U.S. Patent Awarded to AVACEN for Large-Bore Catheter Stabilization Device

AVACEN Inc. has been issued a U.S. utility patent for its CATHeter STAbilization (CATHSTA) device.

CATHSTA is designed for high-acuity applications requiring secure large-bore vascular access, including transcatheter cardiac interventions, mechanical circulatory support, indwelling, extracorporeal membrane oxygenation (ECMO), and renal replacement therapies.

The CATHSTA system provides angle-adaptive mechanical stabilization for large-bore arterial access, helping reduce catheter migration and access-site stress during complex and prolonged procedures. The technology is protected by U.S. Patent No. 12,447,315.

From a commercial perspective, CATHSTA combines a low-COGS, high-margin disposable model with a workflow-neutral design, enabling adoption without procedural disruption or capital investment. The product is intended to scale efficiently through existing global hospital procedural sales channels.

“We are selectively initiating strategic discussions around potential acquisition, licensing, or manufacturing and distribution partnerships for CATHSTA,” AVACEN CEO Thomas Muehlbauer said. “CATHSTA addresses a rapidly expanding market with an expected CAGR approaching 10%, which materially enhances the long-term strategic value of the issued patent.”

AVACEN (Advanced VAscular Circulation ENhancement) develops and markets non-invasive medical devices that enhance microcirculation and support procedural precision. Based in Carlsbad, Calif., AVACEN strives to improve patient outcomes through scientifically supported, patent-protected technologies.